Adela is developing technology to accelerate the diagnosis and improve the management of cancer through blood tests self-described.

Adela

Adela, Inc. | 4,102 followers on LinkedIn. Imagine a world in which a single blood draw can be used to detect and enable early treatment of many different diseases | Adela’s mission is to develop innovative and accessible technologies that harness biology and change the way we diagnose and treat disease.
‍
Adela’s genome-wide methylation enrichment technology was originally developed by Chief Scientific Officer Dr. Daniel De Carvalho, PhD, at University Health Network’s Princess Margaret Cancer Centre.
‍

Karla Jarvis

Mark Taylor

Alan Williams

Associate Director, Clinical Operations at Adela, Inc

Michelle Anderson

Adela, Inc.

November is Lung Cancer Awareness Month—a time to recognize innovative research in the fight against lung cancer. At Adela, we’re committed to advancing breakthroughs that enable earlier diagnosis and improved management of cancer, giving patients a better chance at successful outcomes. Our team works tirelessly to develop and refine methods that can detect cancer and cancer recurrences at their earliest stages, when intervention is most effective. We invite you to visit our website to explore our latest publications and learn more about how we’re contributing to a future where early detection and cancer surveillance saves lives. Together, let’s continue the journey towards a world with fewer cancer diagnoses and more hope. #LungCancerAwareness #EarlyDetection #CancerResearch

Catching head & neck cancer recurrence early🏥 A team led by Drs. Geoffrey Liu and Daniel De Carvalho, PhD at Princess Margaret Cancer Centre (PM), University Health Network and Dr. Anne-Renee Hartman from Adela, Inc. spot head & neck cancer recurrence 14.9 months earlier than standard clinical procedures. They used a blood test that monitors circulating tumour DNA shed from cancer cells. https://lnkd.in/gxF8jXz2 “Currently, the majority of the recurrences are not detected until symptoms or physical findings are reported by the patient. By identifying signals of disease prior to clinical presentation or routine imaging, recurrences can be treated earlier and more effectively," says Dr. Liu, Medical Oncologist and Senior Scientist at PM. The team evaluated a blood test called a molecular residual disease (MRD) test, that can quantify cell free DNA cancer signals to predict and surveil for cancer recurrence. Evaluated in individuals diagnosed with stage I-IVB human papillomavirus (HPV)-positive oropharyngeal and HPV-negative head and neck cancer treated at PM, the full study cohort included >1,100 plasma samples collected from >300 patients. “The test identified disease recurrences up to 14.9 months earlier than the standard of care clinical exam and imaging," says Dr. Liu. Adela’s MRD test was developed based on a discovery published by our Senior Scientist Dr. Daniel De Carvalho and his team. They found that abundant DNA methylation changes in cancer cells detected in the blood could enable low-cost detection, classification and monitoring of cancer. Dr. De Carvalho, together with Dr. Scott Bratman of PM and Dr. Anne-Renee Hartman, Maneesh Jain , and David Scheer co-founded biotech company Adela, Inc. with the support from Commercialization at UHN and institutional investors to translate this discovery into the clinic. Since then, Adela has been finetuning the MRD blood test to be tested and validated in clinical settings for its application. “These strong validation results exemplify the ability of Adela's MRD test to maximize detection of cancer signal in the blood. This single liquid biopsy platform can be applied across cancer types, and we look forward to its impact in other cancer types in the near future," says Dr. De Carvalho, also Chief Scientific Officer of Adela. -------- Research at UHN Published in Annals of Oncology on Sept 14, 2024.

Princess Margaret Cancer Centre Research

The Oncology Venture, Innovation & Partnering Summit is coming up next week (Oct 9-10) in Cambridge, MA and Adela's CEO Lisa Alderson will be sharing her expert opinion on cancer diagnostics, screening, and early detection. Interested in learning more about the Oncology VIP Summit? www.oncologyvipsummit.com #OncologyVIP

Great session on early detection including our CEO Lisa Alderson lined up for tomorrow at the Oliver Wyman Health Innovation Summit!

Thank you Dr. Shao Hui (Sophie) Huang from University Health Network for presenting the blinded clinical validation results for Adela, Inc. 's Head & Neck MRD test at ESMO - European Society for Medical Oncology and for highlighting the importance of a clinically validated, tissue-agnostic MRD test to predict and surveil for recurrence in patients with head & neck cancer. #ESMO #cancerdetection #MRD

Lisa Alderson

Watch the highlights of the clinical validation study of Adela's MRD test in head & neck cancer delivered by Medical Oncologist Dr. Geoff Liu of Princess Margaret Cancer Centre, University Health Network (UHN). https://lnkd.in/g-RAuQtd Research at UHN

Today we are celebrating a significant milestone for Adela: the simultaneous publication of our clinical validation study for our tissue-agnostic MRD test in Head & Neck cancer in Annals of Oncology and its presentation at #ESMO24 . This achievement is a crucial step on our path to making our test available to clinicians and patients in 2025. Currently, the majority of recurrences in patients with head & neck cancer are not detected until symptoms or physical findings are reported by the patient. Our goal is to improve outcomes for patients who have undergone curative treatment for head & neck cancer—regardless of HPV status—by detecting recurrences earlier so they can be treated more effectively. https://lnkd.in/gg-fcyfi https://lnkd.in/gxF8jXz2

If you are attending #ESMO24 don't miss the oral presentation of our clinical validation results demonstrating the ability of our MRD test to predict and monitor for recurrence in patients with head & neck cancer.

We're excited that Scott Bratman , Chief Innovation Officer, is representing Adela as an expert on the topic of MRD testing at the Canaccord Conference this week!

Data recently presented at #ASCO24 showed "MRD detection using [Adela's] cfMeDIP-seq platform correlated strongly with reported recurrence-free survival with hazard ratios consistent with what has been described previously for tumor-informed assays." The presentation by Dr. Liu from Princess Margaret Cancer Center reported on data from a Head & Neck cancer study with Adela, Inc. consisting of a training cohort of 130 patients, of which 45 had a recurrence and 85 did not. https://lnkd.in/gp-tgn2R #MRD #NGS #precisiononcology #futureofcancercare

Metric
Company Name	Adela
Symbol
MSH ID	COM:ADELABIO
Market	PRIVATE
Sector	Healthcare & Health Services
Industry	Biotechnology
Country	CA
Stage
Employee Count
Website	adelabio.com
LinkedIn	adela-inc
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

ADEL

COM:ADELABIO

Adela

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue